Pulmonary immunity to Pseudomonas aeruginosa (Q40966543)

25 September 2017

1 reference

title

Pulmonary immunity to Pseudomonas aeruginosa (English)

1 reference

25 September 2017

Pseudomonas aeruginosa

1 reference

Cripps AW

1

1 reference

25 September 2017

Dunkley ML

series ordinal

2

1 reference

25 September 2017

Clancy RL

series ordinal

3

1 reference

25 September 2017

Kyd J

series ordinal

4

1 reference

25 September 2017

1 October 1995

1 reference

Immunology & Cell Biology

25 September 2017

1 reference

25 September 2017

73

1 reference

25 September 2017

418-424

1 reference

25 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/icb.1995.65

25 September 2017

0 references

cites work

Pseudomonas aeruginosa outer membrane protein OprH: expression from the cloned gene and function in EDTA and gentamicin resistance

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Prevention of invasive pseudomonas infection in burns with a new vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Development of enzyme linked immunosorbent assay (ELISA) to detect antibodies to Pseudomonas aeruginosa cell surface antigens in sera of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Determination of IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Affinity Constants of Naturally Acquired and Vaccine-Induced Anti-Pseudomonas aeruginosa Antibodies in Healthy Adults and Cystic Fibrosis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Immune Complexes in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

An important role for intestinally derived T cells in respiratory defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Controlled trials of a polyvalent pseudomonas vaccine in burns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Pseudomonas aeruginosa vaccine in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

The mucosal immune system: from fundamental concepts to vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Specific protection against acute bronchitis associated with nontypeable Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Reduction in the Incidence of Acute Bronchitis by an OralHaemophilus influenzaeVaccine in Patients with Chronic Bronchitis in the Highlands of Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

Human Immunity to Pseudomonas aeruginosa. I. In-Vitro Interaction of Bacteria, Polymorphonuclear Leukocytes, and Serum Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Serum antibodies to Pseudomonas aeruginosa outer-membrane proteins and iron-regulated membrane proteins at different stages of chronic cystic fibrosis lung infection

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Quantitative analysis of immunoglobulin G subclass responses to Pseudomonas aeruginosa antigens in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Detection by enzyme-linked immunosorbent assays of antibody specific for Pseudomonas proteases and exotoxin A in sera from cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay.

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs.

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Immunologic aspects of surface infections in the lung

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Hypogammaglobulinemia in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

The role of cell-mediated immunity in bacterial infections.

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Cytokines in neutrophil-dominated airway inflammation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Immunization of burned patients against Pseudomonas aeruginosa infection at Safdarjang Hospital, New Delhi

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae.

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

An alteration in the host-parasite relationship in subjects with chronic bronchitis prone to recurrent episodes of acute bronchitis

1 reference

https://api.crossref.org/works/10.1038%2FICB.1995.65

7 January 2021

Identifiers

DOI

10.1038/ICB.1995.65

1 reference

Dimensions Publication ID

25 September 2017

0 references

1 reference